Fresenius SE & Co KGaA (FREG.DE)
Tue, Jul 31 2018
BERLIN Fears that a legal dispute with U.S. drugmaker Akorn could extend into next year overshadowed improved guidance from Germany's Fresenius SE for its Kabi generics business.
* CEO says expect case to be resolved by early 2019 (Adds CEO comments from analyst call)
BERLIN, July 31 Fresenius SE nudged up its earnings guidance for its Kabi generics unit on Tuesday as it posted a 3 percent rise in adjusted group net profit in the second quarter.
FRANKFURT, June 6 German healthcare group Fresenius said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses.
FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.
* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)
* CEO SAYS COSTS RELATED TO AKORN TRANSACTION TOTAL 60 MILLION EUROS SO FAR
FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.
BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.
BERLIN, May 3 German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.